QQQ0.03%

Trending

TSLA5.48%

DCTHDelcath Systems Inc

$10.52

$0.18

(1.67%)

Today

Closed $10.60

$0.08

(0.76%)

After Hours

Updated: 07:24 PM EDT

Reported EarningsMay 7

Mkt Cap$372.14M

Vol598,030.00

Fundamentals

Mkt Cap

$372.14M

Volume

52W High

$17.35

52W Low

$8.12

PE Ratio

1,766.67

Avg. Volume

494,796.60

EPS (Annual)

$0.0676

Rev/Employee

$546,352.56

Earnings

May 07

Extremely Bullish Sentiment

How do you feel about DCTH?

Info

News

all

press releases

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026...

Business Wire

More News

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Companys Compensation Committee, as material...

Business Wire

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New...

Business Wire

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective...

Business Wire

Delcath Systems (DCTH) to Release Quarterly Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-delcath-systems-inc-stock...

MarketBeat

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026...

Business Wire

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the com...

MarketBeat

JPMorgan Chase & Co. Decreases Position in Delcath Systems, Inc. $DCTH

JPMorgan Chase & Co. cut its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 92.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,501 shares of the company's stock after selling 155,744 shares during the period. JPMorgan Chase & Co.'s ho...

MarketBeat

Delcath Systems (NASDAQ:DCTH) Stock Price Up 0.3% - Time to Buy?

Delcath Systems (NASDAQ:DCTH) Shares Up 0.3% - Should You Buy...

MarketBeat

...

Advertisement|Remove ads.